KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) EBIT Margin (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of EBIT Margin data on record, last reported at 13.76% in Q4 2025.

  • For Q4 2025, EBIT Margin rose 338.0% year-over-year to 13.76%; the TTM value through Dec 2025 reached 13.05%, up 413.0%, while the annual FY2025 figure was 13.05%, 413.0% up from the prior year.
  • EBIT Margin reached 13.76% in Q4 2025 per AMRX's latest filing, up from 8.97% in the prior quarter.
  • Across five years, EBIT Margin topped out at 15.37% in Q2 2025 and bottomed at 35.51% in Q2 2022.
  • Average EBIT Margin over 5 years is 6.71%, with a median of 9.14% recorded in 2021.
  • Peak YoY movement for EBIT Margin: plummeted -4805bps in 2022, then soared 4888bps in 2023.
  • A 5-year view of EBIT Margin shows it stood at 2.08% in 2021, then skyrocketed by 184bps to 5.91% in 2022, then plummeted by -61bps to 2.3% in 2023, then soared by 351bps to 10.38% in 2024, then skyrocketed by 33bps to 13.76% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 13.76% in Q4 2025, 8.97% in Q3 2025, and 15.37% in Q2 2025.